|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0600 - 0.0610|
|52 Week Range||0.0600 - 0.1200|
|Beta (3Y Monthly)||-1.58|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Medical Marijuana (OTC: MJNA) subsidiary Phyto Animal Health announced the launch of its newest cannabidiol pet product, Skin Vitality. The salve is intended to treat itching, support muscle and skin recovery and provide relief for hot spots, wounds, bug bites, flea dermatitis and rashes. GB Sciences (OTCQB: GBLX), a partner in GB Sciences Louisiana, said that all cultivation […]The post Cannabis Stock News Daily Roundup April 17 appeared first on Market Exclusive.
Marijuana stocks have been all the rage as legalization for medical and personal use has expanded. Leading the way is superstar Canopy Growth (NYSE:CGC). CGC has been riding high as it continues to see rising sales and has racked up some major deals with blue-chip companies such as Constellation Brands (NYSE:STZ).Source: Shutterstock There's a reason why Canopy could be one of the marijuana stocks first real winners on the race to profitability. Part of the reason is that Canopy is forward thinking.Just as it made some of the first moves into cannabis-infused drinks and other products with its STZ partnership, it's doing so with its latest deals. That will have it front and center in the animal and pet health marketplace. Don't laugh. Petcare is a booming and thriving business. Fertile ground for marijuana stocks to profit.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAnd now, Canopy Growth has the chance to be the leading cannabis stock in the sector. A Big Market for the Marijuana StocksIt's no secret that Americans love their pets. A 2012 Harris Interactive survey found that 9 out 10 respondents viewed their companion pets as a member of the family. The survey also found that these respondents were willing to do whatever is necessary to ensure the health of their pet. And in that love and willingness, many Americans tend to spend almost nearly as much money on them as we do our own children.The American Pet Product Association data shows that annual expenditures by consumers for their pets have grown in each of the last 18 years. This includes during the Great Recession. Last year alone, Americans spent a whopping $72.56 billion on their pets. This includes $18.3 billion on veterinary care and $15.5 billion on supplies and over-the-counter medicines. This year, the APPA estimates that number will surge to more than $75 billion. The truth is, American's are very willing to spend on their fur babies.What does this have to do with marijuana stocks?While cats and dogs are very different than people, they do benefit from some of the same treatments for ailments. A lot of feline and canine drugs have been derived from their human counterparts. For example, our vet prescribes half a Benadryl tablet for our dog when his spring allergies start.With that, it stands to reason that dogs and cats may benefit from similar positive health-effects from cannabinoid and hemp-based CBD products. Already, several studies are underway with the both Colorado State University and the University of Pennsylvania School of Veterinary Medicine looking into CBD treatments for pets with osteoarthritis/joint pain and epilepsy. Meanwhile, just as there is a big and growing market for human supplements using CBD, there's massive potential for pet products as well.For the various marijuana stocks, this is a huge untapped market that they certainly can compete in, now that the Farm Bill has passed and hemp-based CBD is legal in many items. For Canopy Growth, the potential seems very big considering its recent moves. Canopy Growth Could Be the Leading Marijuana Stock for PetsCGC is poised to win in the booming pet care market thanks to another smart partnership. Around the end of March, Canopy cut a deal with Sequential Brands Group. The deal with Sequential puts CGC right into the thick of the pet care market as the collaboration focuses on the pair developing new hemp-derived cannabidiol (CBD) products for animals. The deal was sort of swept under the rug as other marijuana stock news was breaking around that time. But in the deal, was a huge coup for Canopy. And that was Martha Stewart.Yes, that Martha Stewart.The homemaker and entertaining queen provides plenty of brand cache for Canopy as she will become a strategic advisor on the firm's pet and hemp-product lines. Stewart has long been a pet advocative and her chow chows have become stars in their own right. With her on board, sales for whatever CGC develops could quickly find a foothold and command some high market share in the CBD pet product sector.One of the chief reasons why Canopy has been crushing other marijuana stocks has been the strength of its celebrity and major corporate partnerships. The firm has been able to get out in front of some major trends -- like CBD-infused drinks -- and has been able to capitalize on that with big deals. Pets and animal health will be no different. By adding Martha to the mix, it legitimizes its future products and gives it a major edge on supermarket shelves. That's something other pet-focused marijuana stocks like Medical Marijuana, Inc. (NASDAQ:MJNA) or CannTrust Holdings (NYSE:CTST) may not be able to match.All in all, it's just another reason why CGC is pulling away from the pack. Forget the Other Marijuana StocksThe reality is, the pot sector is quickly turning into a one or two horse race with Canopy leading the way. The firm continues to make major transformative deals to get itself out in front of major trends. It's under the rug deal with Sequential Brans puts it right front and center in a huge and growing market. The branding with Martha Stewart will only enhance that further. For investors, it's just another example of why CGC is the cannabis stock to own.As of this writing, Aaron Levitt did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Best Dividend Stocks to Buy for Every Investor * 7 Catalysts That Will Send Marijuana Stocks Soaring in 2019 * 8 Risky Stocks to Watch as Earnings Season Kicks Off Compare Brokers The post Pot for Pets? Canopy Growth Is on the Bleeding-Edge of Marijuana Stocks appeared first on InvestorPlace.
Medical Marijuana (OTC: MJNA) reported that its portfolio company AXIM Biotechnologies (OTCQB: AXIM) has been granted a patent by the United States Patent and Trademark Office (USPTO) for a method to treat atopic dermatitis using cannabinoids. The USPTO has issued a notice of allowance for the patent to the company for a method to treat […]The post AXIM Biotechnologies Gets U.S. Patent for CBD Cream to Treat Atopic Dermatitis appeared first on Market Exclusive.
California-based Medical Marijuana (OTC: MJNA), which makes and sells hemp-based products through subsidiaries, said that its HempMeds subsidiary expanded its retailing network by securing partnerships with more retailers. HempMeds, a retailer and distributor of hemp CBD oil products, formed partnerships with nearly 39 retailers – including major retailer Shopaholic Boutique – to sell its hemp […]The post Medical Marijuana Adds More Locations to Retail Network appeared first on Market Exclusive.
Medical Marijuana, Inc. (OTCMKTS:MJNA) has announced that subsidiary Kannaway® has placed a substantial purchase order from AXIM Biotechnologies (OTCMKTS:AXIM) for its CBD nutraceutical chewing gum. Kannaway® creating a nutraceutical brand Kannaway is a lifestyle network offering CBD hemp products. Blake Schroeder, the Chief Executive Officer, said that the subsidiary was proud to work together with […]The post Medical Marijuana, Inc. Affiliate Kannaway In CBD Gum Partnership With AXIM appeared first on Market Exclusive.
Cannabidiol, or CBD, products are now included in the Prescribers' Digital Reference -- formerly known as the Physicians' Desk Reference -- for the first time ever. The companies are HempMeds and Kannaway, two subsidiaries of Medical Marijuana Inc (OTC: MJNA). Medical Marijuana Inc CEO Stuart Titus told Benzinga the company became the first CBD company to be listed in the Prescribers’ Digital Reference, a book and online database containing drug manufacturers' prescribing information, used by doctors, pharmacists and other health care practitioners across the United States.
Cannabis News PharmaCielo Ltd., the parent company of Colombia's cultivator and producer of medicinal-grade cannabis oil PharmaCielo Colombia Holdings S.A.S., issued a corporate progress update in preparation for its public listing on the TSXV under the ticker PCLO (TSXV:PCLO) on or about January 18. Headquartered in Canada, PharmaCielo is a privately-held firm that focuses on […] The post Cannabis Stock News Daily Roundup January 10 appeared first on Market Exclusive.
Cannabis News Aphria (NYSE: APHA) subsidiary ABP SA has inked a letter of intent with Argentinian state-owned Cannabis Avatãra Sociedad del Estado (CANNAVA) to enter into a cooperation agreement regarding the cultivation of cannabis that will expand the company’s Argentinian operations into the Province of Jujuy. Under the terms of the agreement, ABP will establish […] The post Cannabis Stock News Daily Roundup December 20 appeared first on Market Exclusive.
The 2018 Farm Bill was passed by the Senate on Tuesday by a vote of 87-13. The next move is that the legislation heads to the House for a vote -- and then if it passes there, it goes to President Trump to be signed into law. The impact of this legislation on the cannabis industry is enormous.
The global legal cannabis market is projected to hit $146.4 billion by the end of 2025, according to research by Grand View Research. The legal cannabis industry is gaining traction worldwide due to high demand among consumers for recreational and medical products. Recreational cannabis spending is projected to hit the $35 billion mark, while medical […] The post Cannabis Stock News Daily Roundup November 26 appeared first on Market Exclusive.
While Mexico began Día de Muertos celebrations, the country's Supreme Court offered a gift of epic proportions. One company that’s been strategic about entering the Mexico market is Khiron Life Sciences (OTC: KHRNF). The company recently started an education program by hosting and sponsoring the CannaMexico conference, which former Mexico president Vincente Fox has championed.
It was another busy week for the cannabis industry, with Aurora Cannabis Inc (OTC: ACBFF ) applying to list on the New York Stock Exchange, tobacco giant Altria Group Inc. (NYSE: MO ) reportedly showing ...
In the latest move toward consolidation in the industry, High Times announced Wednesday it has acquired DOPE Media in a split of cash and stock transaction valued at $11.2 million. "The acquisition of Dope Media will be a key building block as we continue on our mission to create brand-safe inventory for brands of all sizes," High Times CEO Adam Levin told Benzinga.
Experts are zeroing in on cannabis as a potential disruptor to the multibillion-dollar prescription-opioid market. According to the 2015 National Survey on Drug Use and Health, 37.8% of the United States adult population was prescribed opioid drugs in 2015. The extremely high rate of prescriptions in the United States as well as internationally has led Grandview Research to forecast the global opioids market to total $34.96 billion by 2025.
Get ready for weed bath bombs, Urban Decay Eyeshadow in Kush and Cannabliss Organic Revitalizing Serum. Medical marijuana may be facing regulatory hurdles across the U.S., but the beauty brands - from small organic store distributors to multinational beauty conglomerates - see a future in cannabis too big to ignore. Beauty "went from something we didn't talk about at all at in the company to this becoming a significant part of our sales," says Schroeder in an interview with Real Money.
The news that GW Pharmaceuticals PLC (ADR) (NASDAQ:GWPH) will soon see Epidiolex, the company’s experimental drug that treats epilepsy, is fantastic in and of itself. Here’s why Epidiolex’s approval should matter to everyone participating in the burgeoning cannabis industry and not just GWPH shareholders. The biggest problem facing the cannabis industry at the moment as it pertains to Cannabidiol (CBD), the main ingredient of Epidiolex, is that hemp-derived CBD is technically considered legal throughout the U.S. as a result of the Agricultural Act of 2014 and exempted from Drug Enforcement Administration (DEA) regulation under a 2006 law, while marijuana-derived CBD is only legal in 30 states and Washington, D.C.
CNBC's Aditi Roy reports on the House's passing of the new Farm Bill and what it may mean for CBD products in the marketplace.